News

GlycoMimetics CEO Rachel King Included Among I95 BUSINESS’ Six Powerful Women Leaders in Life Sciences

Rachel 2018-09-28 Glycomimetics retouch-2-2

Editor’s Note: The Mid-Atlantic region is chocked full of high-profile health care companies that call Maryland home. Many of them are led by brilliant, innovative leaders who just happen to also be women.  Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc. Rachel K. King co-founded GlycoMimetics, Inc. (GMI) in 2003 and has served as its CEO […]

Comments Off on GlycoMimetics CEO Rachel King Included Among I95 BUSINESS’ Six Powerful Women Leaders in Life Sciences Continue Reading →

BioTalk Podcast Gets Inside Scoop on RNADD’s Exclusive License to Cutting-Edge Molecular RNA Dx Platform Technology from UMB and UMBC

block

Dr. Dipanjan Pan and Phil Robilotto of the University of Maryland, Baltimore, join BioTalk to discuss RNA Disease Diagnostics, UM Ventures, and the commercialization of new medical technologies Listen via Apple http://apple.co/3bsUsda, Google http://bit.ly/38l26Vd , Spotify http://spoti.fi/38kp9zu, and TuneIN http://bit.ly/2MVFqDp. Prof. Dipanjan Pan, MS, Ph.D., is an expert in nanomedicine, molecular imaging, drug delivery, and biosensing. He is presently a […]

Comments Off on BioTalk Podcast Gets Inside Scoop on RNADD’s Exclusive License to Cutting-Edge Molecular RNA Dx Platform Technology from UMB and UMBC Continue Reading →

GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer

2019-08-01 Glycomimetics-106_eric feldman

ROCKVILLE, Md.–(BUSINESS WIRE)–Feb. 23, 2021– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development. “Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone […]

Comments Off on GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer Continue Reading →

Sagimet Biosciences Raises $80 Million in Crossover Financing

Sagimet

Altium Capital, HM Capital, Invus, and PFM Health Sciences join previous investors Ascletis, Kleiner Perkins, New Enterprise Associates, Rock Springs Capital, and two undisclosed leading public equity healthcare investors in financing to advance pipeline of FASN inhibitorsCompany also provides update on new board chair and directors San Mateo, California, February 11, 2021 – Sagimet Biosciences, a […]

Comments Off on Sagimet Biosciences Raises $80 Million in Crossover Financing Continue Reading →

RNA Disease Diagnostics, Inc. Takes Exclusive License to Cutting-Edge Molecular RNA Diagnostic Platform Technology from UMB and UMBC

umventures-logo-trans

BALTIMORE, Feb. 4, 2021 /PRNewswire/ — RNA Disease Diagnostics, Inc. (RNADD) has secured an exclusive global license to a cutting-edge sensor technology jointly owned by University of Maryland, Baltimore (UMB) and the University of Maryland, Baltimore County (UMBC). RNADD’s first product will be a rapid point-of-care (POC) COVID-19 test with accuracy, sensitivity, and specificity that is comparable to the gold standard RT-PCR […]

Comments Off on RNA Disease Diagnostics, Inc. Takes Exclusive License to Cutting-Edge Molecular RNA Diagnostic Platform Technology from UMB and UMBC Continue Reading →

Meet Your 2020 BioBuzz Award Winners

BioBuzz-Award-Winners-featured-image

Today, we are excited to announce the winners of our inaugural BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C. The award categories include: The Community Impact Leader […]

MapLight Therapeutics Receives $8.1 Million For Parkinson’s Disease Research

MapLight

SAN FRANCISCO, Nov. 30, 2020 /PRNewswire/ — MapLight Therapeutics today announced a $8.1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to undertake a large-scale, systematic investigation of the brain circuits and mechanisms that are responsible for triggering psychiatric symptoms in Parkinson’s disease. Results will inform identification of novel drug targets and therapeutic strategies to […]

Comments Off on MapLight Therapeutics Receives $8.1 Million For Parkinson’s Disease Research Continue Reading →

GlycoMimetics CEO Rachel King Featured in “Her Story” Podcast Along with BIO’s Dr. Michelle McMurry-Heath

Rachel 2018-09-28 Glycomimetics retouch-2-2

In this conversation, Ms. King and Dr. McMurry-Heath share stories underlying their careers in scientific innovation, from the lab bench to government, consulting, and venture capital; and their experiences as one of the few women CEOs in biotechnology.

Comments Off on GlycoMimetics CEO Rachel King Featured in “Her Story” Podcast Along with BIO’s Dr. Michelle McMurry-Heath Continue Reading →

BioBuzz: Cartesian Therapeutics Pipeline Showcased Among Cutting-Edge Therapies in BioHealth Capital Region

Cartesian Logo New JPG

Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were on display at the 6th annual BioHealth Capital Region Forum. The Strengths of our Region: Cutting Edge Therapies panel, which was moderated by Mark Cobbold, vice president of Discovery in […]

Comments Off on BioBuzz: Cartesian Therapeutics Pipeline Showcased Among Cutting-Edge Therapies in BioHealth Capital Region Continue Reading →